司美替尼在中国1型神经纤维瘤病和不可切除丛状神经纤维瘤成年及儿科患者中的安全性、药代动力学及疗效：一项1期开放标签研究的初步分析 - Suppr

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study.

作者信息

Wang Zhichao, Zhang Xin, Li Chunyan, Liu Yangbo, Ge Xiaoyun, Zhao Jiajia, Yuan Xiaojun, Li Qingfeng

机构信息

Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China.

Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China.

出版信息

Clin Transl Med. 2024 Mar;14(3):e1589. doi: 10.1002/ctm2.1589.

DOI:10.1002/ctm2.1589

PMID:38456222

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10921232/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3a3/10921232/3857796dac19/CTM2-14-e1589-g001.jpg

相似文献

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study.

Clin Transl Med. 2024 Mar;14(3):e1589. doi: 10.1002/ctm2.1589.

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.

Lancet. 2025 Jun 21;405(10496):2217-2230. doi: 10.1016/S0140-6736(25)00986-9. Epub 2025 Jun 2.

Clinical Efficacy of Selumetinib in Alleviating Neuropathic Pain Associated with Plexiform Neurofibroma: A Case Series.

Genes (Basel). 2025 May 28;16(6):645. doi: 10.3390/genes16060645.

Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis.

J Neurol. 2024 May;271(5):2379-2389. doi: 10.1007/s00415-024-12301-8. Epub 2024 Mar 19.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.

Selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature.

Orbit. 2025 Aug;44(4):478-485. doi: 10.1080/01676830.2025.2470989. Epub 2025 Feb 28.

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18.

Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can't be removed by surgery, and impact on how the condition affects caregivers: a plain language summary.

J Comp Eff Res. 2025 Mar;14(3):e240184. doi: 10.57264/cer-2024-0184. Epub 2025 Jan 21.

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

J Clin Oncol. 2021 Mar 1;39(7):797-806. doi: 10.1200/JCO.20.02220. Epub 2021 Jan 28.

Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.

Pediatr Blood Cancer. 2022 Aug;69(8):e29633. doi: 10.1002/pbc.29633. Epub 2022 Mar 15.

引用本文的文献

Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene.

Int J Dev Neurosci. 2025 Oct;85(6):e70049. doi: 10.1002/jdn.70049.

Malignant peripheral nerve sheath tumor in early childhood: a case report of a diagnostic challenge.

Front Oncol. 2025 Jun 24;15:1609477. doi: 10.3389/fonc.2025.1609477. eCollection 2025.

Unraveling novel variants in the NF1 gene and investigating potential therapeutic strategies.

Sci Rep. 2025 Jul 5;15(1):24008. doi: 10.1038/s41598-025-07318-6.

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS.

Front Pharmacol. 2025 Jan 7;15:1454418. doi: 10.3389/fphar.2024.1454418. eCollection 2024.

[Several suggestions for improving diagnosis and management of patients with neurofibromatosis type 1].

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 Oct 15;38(10):1157-1160. doi: 10.7507/1002-1892.202406062.

Selumetinib for plexiform neurofibroma: advances and ongoing challenges.

Neuro Oncol. 2024 Dec 5;26(12):2391-2393. doi: 10.1093/neuonc/noae180.

本文引用的文献

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.

Neurooncol Adv. 2023 May 23;5(1):vdad054. doi: 10.1093/noajnl/vdad054. eCollection 2023 Jan-Dec.

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18.

Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Orphanet J Rare Dis. 2020 Feb 3;15(1):37. doi: 10.1186/s13023-020-1310-3.

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis.

Eur J Clin Pharmacol. 2017 Jun;73(6):717-726. doi: 10.1007/s00228-017-2217-3. Epub 2017 Mar 10.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Neuro Oncol. 2016 May;18(5):624-38. doi: 10.1093/neuonc/nov200. Epub 2016 Feb 6.

The NF1 gene revisited - from bench to bedside.

Oncotarget. 2014 Aug 15;5(15):5873-92. doi: 10.18632/oncotarget.2194.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献